Treatment of CVID - What is the evidence?

CPD Bulletin Immunology and Allergy

Volumn 2, Issue 2, 2002, Pages 48-51

  Stroud, Catherine ^a   Bourne, Helen ^a   Spickett, Gavin ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Antibiotics; Common variable immunodeficiency; Cytokines; Immunodeficiency; IVIG

Indexed keywords

ANTIBIOTIC AGENT; CIMETIDINE; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; KETOPROFEN; LIPOXYGENASE INHIBITOR; POLIOMYELITIS VACCINE; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT INTERLEUKIN 2; RETINOL; RETINOL DERIVATIVE; STEROID; VACCINE;

ADD ON THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; EVIDENCE BASED MEDICINE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFECTION; PHYSIOTHERAPY; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SKIN GRANULOMA;

EID: 0036247614     PISSN: 13678949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Primary immunodeficiency disorders in Sweden: Cases among children 1974-1979
2. Common variable immunodeficiency: How many diseases?
3. Diagnostic criteria for primary immunodeficiencies
4. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment
5. Use of Intravenous gammaglobulin in antibody deficiency; Results of a multicenter controlled trial
6. Intravenous immunoglobulin therapy for antibody deficiency
7. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease
8. Benefit of intravenous IgG replacement in hypogammaglobinaemic patients with chronic sinopulmonary disease
9. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobinaemia
10. Efficacy and safety of high dose IVIG therapy for antibody deficiency syndromes
11. High dose versus low dose IVIG in hypogammaglobulineamia and chronic lung disease
12. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobinaemia; A retrospective survey of 31 patients
13. Individual patient variations in the kinetics of intravenous immunoglobulin administration
14. The half lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin
15. Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases
16. Home intravenous immunoglobulin therapy by self administration
17. Immunoglobulin replacement by self infusion at home
18. Home treatment of hypogammaglobinaemia with subcutaneous immunoglobulin by Rapid Infusion
19. Rapid subcutaneous immunoglobulin infusions in children
20. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
21. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG sufficient children with recurrent infections and poor resonse to immunisation with haemophilus influenza type b capsular polysaccharide
22. Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies
23. Prolonged polio virus excretion in an immunodeficient person with vaccine associated paralytic poliomyelitis
24. Localised pulmonary resection for bronchiectasis in hypogammaglobuliaemic patients
25. Summary of antibody deficiency audit 1993-1996. CPD Bulletin
26. Interleukin-2 correction of defective in vitro T cell mitogenesis in patients with common varied immunodeficiency
27. Defective T cell activation in common variable immunodeficiency is restored by phorbol myristatic acetate (PMA) or allogeneic macrophages
28. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2
29. Stimulation of de novo antibody production and IL-2 secretion in vivo in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2
30. Enhanced humoral immunity in common variable immunodeficiency after long term treatment with polyethylene glycol-conjugated interleukin-2
31. A double blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID)
32. Improved in vitro antigen-specific antibody synthesis in two patients with common variable immunodeficiency taking and oral cyclooxygenase and lipoxygenase inhibitor (ketoprofen)
33. Granulomatous disease in common variable immunodeficiency: Effect on immunoglobulin replacement therapy and response to steroids and splenectomy
34. Cutaneous granulomas in children with combined immunodeficiency
35. Granulomatous disease in common variable immunodeficiency
36. Cutaneous and hepatic granulomas in a young woman with common variable immunodeficiency
37. Decreased vitamin A levels in common variable immunodeficiency; Vitamin A supplementation in vivo enhances immunoglobulin production and downregulates inflammatory responses
38. The effects of vitamin A derivatives on in vitro antibody production by peripheral blood mononuclear cells (PBMC) from normal blood donors and patients with common variable immunodeficiency (CVID)
39. Long term administration of 13-cis retinoic acid in common variable immunodeficiency; Circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production
40. Common variable immunodeficiency: A family study and therapeutic trial with cimetidine